Nuvo Pharmaceuticals Inc., a healthcare company, provides prescription and non-prescription products for pain, allergy, and dermatology in the United States, Canada, Europe, and internationally. The company operates through three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial; Cambia, a nonsteroidal anti-inflammatory drug for the treatment of migraine; Resultz, a non-prescription product intended to kill head lice and remove their eggs from hair; and Suvexx/Treximet, a medicine for migraine. The company also provides Pennsaid, a topical pain product that is used to treat the signs and symptoms of osteoarthritis of the knee; Pennsaid 2%, a follow-on product to Pennsaid; Vimovo for relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; Yosprala for secondary prevention of cardiovascular and cerebrovascular events; and Heated Lidocaine/Tetracaine (HLT) Patch, a topical patch applied prior to painful medical procedures, such as venous access, blood draws, needle injections and minor dermatologic surgical procedures. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was founded in 1983 and is headquartered in Mississauga, Canada.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for NRIFF